What's in Vrije Universiteit Brussel's pipeline?

Vrije Universiteit Brussel has 7 drugs in our index: 5 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Vrije Universiteit Brussel's portfolio?

Top competitors by shared drug class: Pontificia Universidad Catolica de Chile, University of Wisconsin, Madison, Ain Shams University, Ankara Yildirim Beyazıt University, Atlantic Health System.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vrije-universiteit-brussel.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Vrije Universiteit Brussel — Portfolio Competitive Intelligence Brief

Vrije Universiteit Brussel pipeline: 5 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Lidocaine infiltration	Lidocaine infiltration	marketed	Local anesthetic	Voltage-gated sodium channels	Anesthesia
Intravenous bumetanide TID	Intravenous bumetanide TID	marketed
Oral potassium supplements	Oral potassium supplements	marketed
Oral chlorthalidone OD	Oral chlorthalidone OD	marketed
Xylocaine with Epinephrine	Xylocaine with Epinephrine	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors	Anesthesia
Reboxetine Pill	Reboxetine Pill	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)	Psychiatry / Neurology
Methylphenidate Oral Product	Methylphenidate Oral Product	phase 3	Central nervous system stimulant; sympathomimetic amine	Dopamine transporter (DAT); Norepinephrine transporter (NET)	Neurology; Psychiatry

Therapeutic area mix

Anesthesia · 2
Neurology; Psychiatry · 1
Psychiatry / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pontificia Universidad Catolica de Chile · 2 shared drug classes
University of Wisconsin, Madison · 2 shared drug classes
Ain Shams University · 1 shared drug class
Ankara Yildirim Beyazıt University · 1 shared drug class
Atlantic Health System · 1 shared drug class
Aultman Health Foundation · 1 shared drug class
Axsome Therapeutics, Inc. · 1 shared drug class
Aligarh Muslim University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vrije Universiteit Brussel:

Cite this brief

Drug Landscape (2026). Vrije Universiteit Brussel — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vrije-universiteit-brussel. Accessed 2026-05-16.